Mirvetuximab Soravtansine vs Nivolumab

## Mirvetuximab Soravtansine vs Nivolumab: Overview

This comparison examines the pharmacological differences between **Mirvetuximab Soravtansine** and **Nivolumab**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Mirvetuximab Soravtansine — N/A; Nivolumab — 27 days.

## Chemical Properties

**Type**: Mirvetuximab Soravtansine — Antibody drug conjugate; Nivolumab — Antibody.